Commentary: Risks and Benefits,Testing and Screening,Cancer,Genes and Dollars

See Kahn P. , “Coming to Grips with Genes and Risk,” Science, 274 (1996): 496–98.

See Wilfond B. , “Cancer Genetic Susceptibility Testing: Ethical and Policy Implications for Future Research and Clinical Practice,” Journal of Law, Medicine & Ethics, 25 (1997): 243–51.

See Task Force on Genetic Information and Insurance, National Center for Human Genome Research, Genetic Information and Health Insurance (Bethesda: National Institutes of Health, 1993).

See Wilfond , supra note 2, at 248.

See Hoskins K.F. , “Assessment and Counseling for Women with a Family History of Breast Cancer,” JAMA, 273 (1995): 577–85.

See Biesecker B.B. Boehnke M. Calzone K. , “Genetic Counseling for Families with Inherited Susceptibility to Breast and Ovarian Cancer,” JAMA, 269 (1993): 1970–74.

See Wilfond , supra note 2, at 243.

See Rimer B.K. Schildkraut J. , “Cancer Screening,” in DeVita V.T. Hellman S. Rosenberg S.A. , eds., Cancer: Principles and Practice of Oncology (Philadelphia: Lippincott-Raven, 5th ed., 1997): Ch. 25.

See Motulsky A.G. , “Screening for Genetic Diseases,” N. Engl. J. Med., 336 (1997): 1314–16.

See Rimer Schildkraut , supra note 8, at 619.

See Kramer B.S. , “The Screening Editorial Board of the Physician Data Query: NCI State of the Art Statements on Cancer Screening” in Greenwall P. Kramer B.S. Weed D.L. , eds., Cancer Prevention and Control (New York: Marcel Dekker, 1995): 719–22.

See, for example, Collins F.S. , “Statement on the Use of DNA Testing for Presymptomatic Identification of Cancer Risk,” JAMA, 271 (1994): 785; and American Society of Clinical Oncology, “Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility,” Journal of Clinical Oncology, 14 (1996): 1730–36.

See Schulman J.D. Stern H.J. , “Genetic Predisposition Testing for Breast Cancer” (visited Feb. 18, 1998) <http://www.givf.com/cancer_Journal1.html> (reprint from The Cancer Journal (1996)).

See Myriad Genetics, A Corporate Commitment to Responsible Genetic Testing (visited Oct. 14, 1996) <http://www.myriad.com/Commitment>.

Id. at 1.

See Hubbard R. Lewontin R.C. , “Pitfalls of Genetic Testing,” N. Engl. J. Med., 334 (1996): 1192–94.

For example, Myriad Genetics, OncorMed, and Genetics IVF Institute.

See Rosenberg S.A. , “Secrecy in Medical Research,” N. Engl. J. Med., 334 (1996): 392–94.

See Kodish E. Whitehouse P. Murray T. , “Conflict of Interest in University-Industry Research Relationships: Realities, Politics and Values,” Academic Medicine, 71 (1996): 7–10.

See Fletcher S.W. , “Whither Scientific Deliberation in Health Policy Recommendations?,” N. Engl. J. Med., 336 (1997):1180–83.

See Chodak G. , “Prostate Cancer: To Screen or Not to Screen,” Acta Oncologica, 30 (1991): 285–87.

See Kodish E. , “Genetic Testing for Cancer Risk: How to Reconcile the Conflict,” JAMA, 279 (1998): 179–81.